| 摘要 |
The present invention pertains to the field of toxicological assessments for risk stratification of chemical compounds. Specifically, it relates to a method for diagnosing increased peroxisomal proliferation. It also relates to a method of determining whether a compound is capable of inducing such peroxisomal proliferation in a subject and to a method of identifying a drug for treating increased peroxisomal proliferation. Furthermore, the present invention relates to a data collection comprising characteristic values of at least five metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing increased peroxisomal proliferation. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing increased peroxisomal proliferation in a subject. |
| 主权项 |
1. A method for diagnosing a disorder associated with increased peroxisomal proliferation comprising:
(a) selecting a male or female subject suspected to suffer from increased peroxisomal proliferation; (b) obtaining a body fluid test sample from the male or female subject; (c) determining the amount of at least five of the following analytes Coenzyme Q10, 16-Methylheptadecanoic acid, 17-Methyloctadecanoic acid, Eicosatrienoic acid (C20:3), Threonine, Proline, Tyrosine, trans-4-Hydroxyproline from the body fluid test sample from the male subject, or the amount of at least five of the following analytes Pantothenic acid, Coenzyme Q9, Glycerol, Palmitic acid (C16:0), Linoleic acid (C18:cis[9,12]2), 14-Methylhexadecanoic acid, gamma-Linolenic acid (C18:cis[6,9,12]3), 16-Methylheptadecanoic acid, Threonic acid, Cytosine, Phosphatidylcholine (C18:0/C22:6) from the body fluid test sample from the female subject; (d) comparing the amounts determined in step (c) to corresponding reference results, wherein the reference results comprise
(i) reference results obtained from one or more samples derived from one or more subjects which has been brought into contact with Benzylbutyl Phthalate, Fenofibrate, Clofibrate, Fenoforbrate, Diethylhexylphthalate or Wy 14643,(ii) reference results obtained from one or more samples derived from one or more subjects which has not been brought into contact with Benzylbutyl Phthalate, Fenofibrate, Clofibrate, Fenoforbrate, Diethylhexylphthalate or Wy 14643,(iii) reference results obtained from one or more samples derived from one or more subjects which suffers from increased peroxisomal proliferation, or(iv) reference results obtained from one or more samples derived from one or more subjects known to not suffer from increased peroxisomal proliferation; and (e) based on the comparison of step (d), diagnose the disorder by monitoring, confirmation, or classification of the disorder or its symptoms in the male or female subject. |
